Brown, Lisle/Cummings, Inc. Viatris Inc Transaction History

Brown, Lisle/Cummings, Inc.

$307 Billion
Q2 2024

A detailed history of Brown, Lisle/Cummings, Inc. transactions in Viatris Inc stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 1,183 shares of VTRS stock, worth $14,006. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,183

Previous 3,033 61.0%

Holding current value

$14,006

Previous $36.2 Million 65.28%

% of portfolio

0.0%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 17, 2024	SELL	$10.05 - $12.02 $18,592 - $22,237	-1,850 Reduced 61.0%	1,183 $12.6 Million
Q1 2024 Jun 28, 2024	BUY	$11.27 - $13.53 $11,067 - $13,286	982 Added 47.88%	3,033 $36.2 Million
Q4 2023 Jun 28, 2024	SELL	$8.77 - $10.85 $30,002 - $37,117	-3,421 Reduced 62.52%	2,051 $22.2 Million
Q3 2023 Jun 28, 2024	SELL	$9.59 - $11.35 $44,957 - $53,208	-4,688 Reduced 46.14%	5,472 $54 Million
Q2 2023 Jun 28, 2024	SELL	$9.02 - $10.29 $9,020 - $10,290	-1,000 Reduced 8.96%	10,160 $101 Million

Q1 2023 Jun 28, 2024	SELL	$9.2 - $12.26 $9,200 - $12,260	-1,000 Reduced 8.22%	11,160 $107 Million
Q4 2022 Jun 28, 2024	BUY	$8.72 - $11.56 $2,528 - $3,352	290 Added 2.44%	12,160 $135 Million
Q3 2022 Jun 28, 2024	SELL	$8.48 - $11.13 $6,410 - $8,414	-756 Reduced 5.99%	11,870 $101 Million
Q2 2022 Jun 28, 2024	SELL	$9.95 - $12.27 $25,133 - $30,994	-2,526 Reduced 16.67%	12,626 $132 Million
Q1 2022 Jun 28, 2024	BUY	$9.81 - $15.4 $32,000 - $50,234	3,262 Added 27.43%	15,152 $165 Million
Q4 2021 Jun 28, 2024	BUY	$12.09 - $14.68 $143,750 - $174,545	11,890 New	11,890 $161 Million

Others Institutions Holding VTRS

# of Institutions

1,104

Shares Held

946M

Call Options Held

3.49M

Put Options Held

2.6M

View Full List

About Viatris Inc

Ticker VTRS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 1,212,669,952
Market Cap $14.4B
Description
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, i...

More about VTRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown, Lisle/Cummings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Brown, Lisle/Cummings, Inc. with notifications on news.

Account

Brown, Lisle/Cummings, Inc. Viatris Inc Transaction History